Stereo Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 10-12-2024
- Paid Up Capital ₹ 3.00 Cr
as on 10-12-2024
- Company Age 16 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 17.06 Cr
as on 10-12-2024
- Revenue -41.27%
(FY 2022)
- Profit 147.77%
(FY 2022)
- Ebitda -67.13%
(FY 2022)
- Net Worth 0.39%
(FY 2022)
- Total Assets -8.25%
(FY 2022)
About Stereo Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company has closed loans amounting to ₹17.06 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Akkisani and Prathima Arveti serve as directors at the Company.
- CIN/LLPIN
U24233TG2008PTC059539
- Company No.
059539
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jun 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Stereo Drugs Private Limited offer?
Stereo Drugs Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Chemical Intermediates, Pharma Ingredients & Raw Materials, API Intermediate.
Who are the key members and board of directors at Stereo Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akkisani  | Managing Director | 01-Dec-2022 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Prathima Arveti | Director | 17-Aug-2023 | Current |
Financial Performance of Stereo Drugs.
Stereo Drugs Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 41.27% decrease. The company also saw a substantial improvement in profitability, with a 147.77% increase in profit. The company's net worth moved up by a moderate rise of 0.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stereo Drugs?
In 2023, Stereo Drugs had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aura Research And Remedies Private LimitedActive 3 years 9 monthsAkkisani and Prathima Arveti are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 17 Feb 2014 | ₹0.54 M | Satisfied |
Axis Bank Limited Creation Date: 31 Oct 2013 | ₹11.86 Cr | Satisfied |
Corporation Bank Creation Date: 22 Aug 2011 | ₹5.14 Cr | Satisfied |
How Many Employees Work at Stereo Drugs?
Stereo Drugs has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stereo Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stereo Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
